IHC-P analysis of human breast carcinoma tissue using GTX87014 LATS1 + LATS2 antibody. The picture on the right is blocked with the synthesized peptide.
IHC-P analysis of human breast carcinoma tissue using GTX87014 LATS1 + LATS2 antibody. The picture on the right is blocked with the synthesized peptide.
LATS1 + LATS2 antibody
GTX87014
ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetLATS1
Overview
- SupplierGeneTex
- Product NameLATS1 + LATS2 antibody
- Delivery Days Customer9
- Application Supplier NoteIHC-P: 1:50~1:100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID9113
- Target nameLATS1
- Target descriptionlarge tumor suppressor kinase 1
- Target synonymsh-warts; large tumor suppressor homolog 1; LATS (large tumor suppressor, Drosophila) homolog 1; LATS, large tumor suppressor, homolog 1; serine/threonine-protein kinase LATS1; WARTS; WARTS protein kinase; wts
- HostRabbit
- IsotypeIgG
- Protein IDO95835
- Protein NameSerine/threonine-protein kinase LATS1
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Outcome in serous ovarian cancer is not associated with LATS expression. Montavon C et al., 2019 Nov, J Cancer Res Clin OncolRead more